| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Tetrabutylammonium hydrogensulfate does not have a defined pharmacological target. It is a phase-transfer catalyst that facilitates the transfer of reactants between immiscible phases in organic synthesis. Its mechanism of action is physical, involving the formation of ion pairs that enable ionic species to be transported into organic phases.
|
|---|---|
| ln Vitro |
Tetrabutylammonium hydrosulfate is a biochemical reagent that can be utilized in studies pertaining to life sciences as an organic substance or biological material.
In vitro, tetrabutylammonium hydrogensulfate is used as a phase-transfer catalyst in organic synthesis reactions. It is also used as an electrolyte in electrochemical applications. As a quaternary ammonium salt, it is a common reagent for facilitating reactions between aqueous and organic phases. |
| ln Vivo |
In vivo activity data for tetrabutylammonium hydrogensulfate are not available, as the compound is a phase-transfer catalyst and chemical reagent used for in vitro applications. It is not intended for in vivo administration and has no established in vivo pharmacokinetic or pharmacodynamic profile.
|
| Enzyme Assay |
For in vitro chemical synthesis, tetrabutylammonium hydrogensulfate is used as a phase-transfer catalyst. The compound is added to biphasic reaction mixtures (typically aqueous-organic) at catalytic amounts (1-10 mol%). It facilitates the transfer of ionic reactants or reagents from the aqueous phase to the organic phase, enabling reactions to proceed. The compound is also used as an electrolyte in electrochemical experiments.
|
| Cell Assay |
For in vitro cell-based experiments, tetrabutylammonium hydrogensulfate is not typically used directly in cell culture. It is a phase-transfer catalyst and chemical reagent used for organic synthesis. The compound may be used in the synthesis of compounds that are subsequently tested in cell-based assays, but it is not added directly to cell cultures as a test compound.
|
| Animal Protocol |
In vivo animal studies for tetrabutylammonium hydrogensulfate are not applicable, as the compound is a phase-transfer catalyst used for chemical synthesis. No animal studies have been conducted for this compound as a therapeutic agent, and it is not intended for diagnostic or therapeutic use in animals or humans.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for tetrabutylammonium hydrogensulfate are not available, as the compound is not a drug and is not administered to living organisms. The compound has a molecular weight of 339.54 g/mol. As a charged quaternary ammonium salt, it is expected to have very low oral bioavailability and poor membrane permeability.
|
| Toxicity/Toxicokinetics |
Tetrabutylammonium hydrogensulfate is a research chemical and should be handled with appropriate laboratory safety precautions. As a quaternary ammonium salt, it may cause skin and eye irritation. The compound is for research use only and not for human therapeutic or diagnostic applications. Specific LD₅₀ values and acute toxicity classifications are not available.
|
| Additional Infomation |
Tetrabutylammonium hydrogensulfate (TBAHS, CAS 32503-27-8) is primarily a research-grade chemical reagent, not an FDA-approved pharmaceutical drug. Its primary applications are as a phase-transfer catalyst in organic synthesis and as an electrolyte in electrochemical applications. No clinical trials or approved therapeutic indications exist.
|
| Molecular Formula |
C16H37NO4S
|
|---|---|
| Molecular Weight |
339.53
|
| Exact Mass |
339.244
|
| CAS # |
32503-27-8
|
| Related CAS # |
10549-76-5 (Parent)
|
| PubChem CID |
94433
|
| Appearance |
White to off-white solid powder
|
| Density |
1.010 g/cm3
|
| Melting Point |
171-174 °C
|
| LogP |
5.089
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
22
|
| Complexity |
192
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCC[N+](CCCC)(CCCC)CCCC.[O-]S(=O)(O)=O
|
| InChi Key |
SHFJWMWCIHQNCP-UHFFFAOYSA-M
|
| InChi Code |
InChI=1S/C16H36N.H2O4S/c1-5-9-13-17(14-10-6-2,15-11-7-3)16-12-8-4;1-5(2,3)4/h5-16H2,1-4H3;(H2,1,2,3,4)/q+1;/p-1
|
| Chemical Name |
hydrogen sulfate;tetrabutylazanium
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9452 mL | 14.7262 mL | 29.4525 mL | |
| 5 mM | 0.5890 mL | 2.9452 mL | 5.8905 mL | |
| 10 mM | 0.2945 mL | 1.4726 mL | 2.9452 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
